IFF · International Flavors & Fragrances Inc

Track IFF — free

$87.95 +1.10 (+1.27%) At close · Aug 28

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$22.44B

255.15M

Up next

Next earnings call

Nov 4, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 4, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Research

our published analysis of this company

Buybacks Roundup August 10, 2026

MetLife Tops a $15.3B Buyback Week; First-Timers Dominate the Field

Ten repurchase authorizations totaling $15.3B were announced in the week ended August 9, 2026, led by MetLife's $3.0B program. Nine of the ten are first-time repurchasers on Equibles' records, and the heaviest hitters sit near 52-week highs.

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Moderate

Market backdrop VIX 14.4 · calm Equity put/call 0.62

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +19%

above

Price vs 50-day avg +9%

above

RSI (14) 65

neutral

MACD trend Positive

52-week position 100%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +11%

trailing

6-month return +20%

trailing

YTD return +31%

this year

Relative strength +7%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $80 › 200d $74 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +115 funds added

Insider flow Accumulating

Net +$19.0M over 90 days · 75% sells

Short interest Falling

6.02% of float · ▼ -6.4% MoM · 8.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

756 holders — mid 3-yr range

Squeeze score 72

high risk · 0–100

Fundamentals

Fair

Revenue growth −5%

Y/Y

Gross margin 36%

expanding

EPS growth −236%

Y/Y

Free cash flow $256.0M

Valuation P/E 80

rich

Buyback $400.0M

remaining

Balance sheet $5.0B

net debt

Quant / Vol

risk profile

Moderate

Volatility 36%

annualized · 1-yr

Max drawdown −20%

past year

ATR 2.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 5 of last 5

Latest guidance · from the 8-K filed Aug 4, 2026

full year 2026

Sales Lowered $7.4B – $7.6B

May 5, 2026 $10.5B – $10.8B Aug 4, 2026 $7.4B – $7.6B

prior FY $10.89B midpoint −31.1% Y/Y

Adjusted operating EBITDA Non-GAAP Lowered $1.53B – $1.6B

May 5, 2026 $2.05B – $2.15B Aug 4, 2026 $1.53B – $1.6B

2026

Sales growth impact of foreign exchange 1%

Adjusted operating EBITDA growth impact of foreign exchange Non-GAAP 2%

second half of 2026

Accelerated share repurchase Initiated $500M

Prior guidance period ended · from the 8-K filed Nov 4, 2025

Sales · full year 2025 $10.6B – $10.9B

Adjusted operating EBITDA · full year 2025 $2B – $2.15B

Comparable currency neutral adjusted operating EBITDA growth · full year 2025 5% – 10%

Guided vs delivered · last 5 settled

Sales full year 2025

guided $10.6B – $10.9B

guided $10.6B – $10.9B $10.89B In line

Sales full year 2024

guided $10.8B – $11.1B

guided $10.8B – $11.1B $11.48B Beat +4.9%

Sales first quarter

guided $2.7B – $2.8B

guided $2.7B – $2.8B $2.9B Beat +5.4%

Full year revenue full year 2023

guided $11.3B – $11.6B

guided $11.3B – $11.6B $11.48B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+19% Bullish

Price vs 50-day avg

+9% Bullish

RSI (14)

65 Neutral

MACD trend

Positive Bullish

52-week position

100% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $80 › 200d $74 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +115 funds added

Insider flow Accumulating

Net +$19.0M over 90 days · 75% sells

Short interest Falling

6.02% of float · ▼ -6.4% MoM · 8.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

756 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $60 Now $88 · 100% Range high $88

vs 200-day avg +19% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
% Change in Adjusted Operating EBITDA - Pharma Solutions (Reported) non-GAAP	-100%	Second Quarter 2026 vs. Second Quarter 2025 filing	—
% Change in Adjusted Operating EBITDA - Scent (Reported) non-GAAP	11%	Second Quarter 2026 vs. Second Quarter 2025 filing	—
Adjusted (Non-GAAP) EPS ex. Amortization non-GAAP	$1.74	Six Months Ended June 30, 2026	—

Adjusted Operating EBITDA from Continuing Operations non-GAAP	$841M	Six Months Ended June 30, 2026	—
Adjusted Operating EBITDA from Discontinued Operations non-GAAP	$275M	Six Months Ended June 30, 2026	—
Consolidated Segment Adjusted Operating EBITDA Margin non-GAAP	20.6%	Three Months Ended June 30, 2026	—

Credit Adjusted EBITDA non-GAAP	$2.06B	Twelve Months Ended June 30, 2026	-2.1%

GAAP → non-GAAP reconciliation GAAP Net income 254M +187M Interest expense +98M Income taxes +948M Depreciation and amortization +341M Specified items +228M Non-cash items = Credit Adjusted EBITDA 2.06B
Free cash flow non-GAAP	$378M	First Six Months 2026	—
Health & Biosciences adjusted operating EBITDA non-GAAP	$150M	Q2 2026	—

Health & Biosciences Adjusted Operating EBITDA Margin non-GAAP	24.7%	Six Months Ended June 30, 2026	—

Health & Biosciences Segment Adjusted Operating EBITDA non-GAAP	$277M	Six Months Ended June 30, 2026	—
Health & Biosciences Segment Adjusted Operating EBITDA Margin non-GAAP	24.4%	Six Months Ended June 30, 2026	—

Operating EBITDA non-GAAP	$408M	Q2 2026	—
Operating EBITDA Margin non-GAAP	20.9%	Q2 2026	—

Scent adjusted operating EBITDA non-GAAP	$134M	Q2 2026	—

Scent Adjusted Operating EBITDA Margin non-GAAP	20.9%	Six Months Ended June 30, 2026	—

Scent Segment Adjusted Operating EBITDA non-GAAP	$258M	Six Months Ended June 30, 2026	—
Scent Segment Adjusted Operating EBITDA Margin non-GAAP	20.3%	Six Months Ended June 30, 2026	—

Segment Adjusted Operating EBITDA non-GAAP	$803M	Six Months Ended June 30, 2026	—

Taste adjusted operating EBITDA non-GAAP	$124M	Q2 2026	—

Taste Adjusted Operating EBITDA Margin non-GAAP	20.2%	Six Months Ended June 30, 2026	—

Taste Segment Adjusted Operating EBITDA non-GAAP	$268M	Six Months Ended June 30, 2026	—
Total IFF Adjusted Operating EBITDA Inclusive of Discontinued Operations non-GAAP	$1.12B	Six Months Ended June 30, 2026	—
Adjusted operating EBITDA non-GAAP	$568M	first quarter 2026	—

Food Ingredients adjusted operating EBITDA non-GAAP	$114M	first quarter 2026	—

Food Ingredients adjusted operating EBITDA margin non-GAAP	13.6%	first quarter 2026	—

Net debt non-GAAP	$5.29B	March 31, 2026	—
GAAP → non-GAAP reconciliation GAAP Total debt 5.85B -562M Cash and cash equivalents = Net debt 5.29B
Adjusted (Non-GAAP) EPS non-GAAP	$2.52	Year Ended December 31, 2025	—
Adjusted (Non-GAAP) Net Income non-GAAP	$645M	Year Ended December 31, 2025	—
Adjusted (Non-GAAP) Net Income ex. Amortization non-GAAP	$1.08B	Year Ended December 31, 2025	—
Food Ingredients Segment Adjusted Operating EBITDA Margin non-GAAP	12.9%	Twelve Months Ended December 31, 2025	—
Pharma Solutions Adjusted Operating EBITDA non-GAAP	$76M	Twelve Months Ended December 31, 2025	—
Pharma Solutions Segment Adjusted Operating EBITDA Margin non-GAAP	20.6%	Twelve Months Ended December 31, 2025	—
Taste Segment Adjusted Operating EBITDA Margin non-GAAP	19.3%	Twelve Months Ended December 31, 2025	—
Total Adjusted Operating EBITDA non-GAAP	$2.09B	Twelve Months Ended December 31, 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Specialty Chemicals — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IFF International Flavors & Fragrances Inc this stock	$22.44B	+30.5%	-5.2%	80.0	6.0%
LIN Linde PLC	$225.65B	+14.8%	+3.0%	31.6	1.1%
AIQUF L Air Liquide SA /Fi	$126.15B	+5.6%	—	—	0.0%
SHW Sherwin Williams Co	$83.55B	+6.4%	+2.1%	31.8	2.6%
ECL Ecolab Inc.	$80.38B	+9.2%	+2.2%	38.5	1.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

756

% held: 107.1%
Net QoQ: +15.4M sh
Top holder: Dodge & Cox

Held Float

View

Held by Funds

Fund positions

673

View

Short & Settlement

Short Interest Falling

Shares short

15.4M

Days to cover: 8.5d
Change: -1.1M sh

View

Short Volume

Short vol %

66%

As of: Aug 28, 2026

Short Total

View

Fails to Deliver

FTD shares

205

Value: $16.3K
As of: Jul 30, 2026

View

Off-Exchange

Off-exchange %

42.7%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$19.0M

Buyers / Sellers: 1 / 3

Buyers Sellers

View

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: Nov 18, 2025

View

Financials

Revenue (FY)

$10.9B

Net income (FY): $339.8M
EPS diluted: $-1.41

View

Buybacks

Authorized · 3 programs

$5.0B

Remaining: $400.0M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 4, 2026
This year: 12

View

Proposed Sales

Value

$475.7K

Shares: 5.7K
Filed: Aug 17, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 5, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
IFF	+4.4%	+11.0%	+20.2%	+11.0%	+30.5%
SPY	+0.5%	+3.0%	+13.4%	+3.0%	+12.8%
vs SPY	+3.9%	+8.0%	+6.8%	+8.0%	+17.7%

Capital returns

Latest dividend

$0.40 / share · ex Jun 18, 2026

Declared · upcoming

$0.40 / share · ex Sep 18, 2026

Cut 50.6%

Paid (TTM)

$1.60 / share · 4 payouts

Dividend yield (TTM, derived)

1.82%

Buyback programs · 3 active · as of Aug 4, 2026

Authorized (total)

$5.00B

Spent (derived)

$4.60B

Remaining

$400.00M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 51253 CUSIP 459506101 13F (30d) 523 filings 501 filers Visit website Investor relations

IFF · International Flavors & Fragrances Inc

Price & Indicators

Up next

AI Brief

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns